These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 35017153)

  • 1. Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments.
    Moreno-Vicente J; Willoughby JE; Taylor MC; Booth SG; English VL; Williams EL; Penfold CA; Mockridge CI; Inzhelevskaya T; Kim J; Chan HTC; Cragg MS; Gray JC; Beers SA
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy.
    Cohen Saban N; Yalin A; Landsberger T; Salomon R; Alva A; Feferman T; Amit I; Dahan R
    Sci Immunol; 2023 Mar; 8(81):eadd8005. PubMed ID: 36867679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy.
    Arlauckas SP; Garris CS; Kohler RH; Kitaoka M; Cuccarese MF; Yang KS; Miller MA; Carlson JC; Freeman GJ; Anthony RM; Weissleder R; Pittet MJ
    Sci Transl Med; 2017 May; 9(389):. PubMed ID: 28490665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy.
    McAuliffe J; Chan HF; Noblecourt L; Ramirez-Valdez RA; Pereira-Almeida V; Zhou Y; Pollock E; Cappuccini F; Redchenko I; Hill AV; Leung CSK; Van den Eynde BJ
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner.
    Peper-Gabriel JK; Pavlidou M; Pattarini L; Morales-Kastresana A; Jaquin TJ; Gallou C; Hansbauer EM; Richter M; Lelievre H; Scholer-Dahirel A; Bossenmaier B; Sancerne C; Riviere M; Grandclaudon M; Zettl M; Bel Aiba RS; Rothe C; Blanc V; Olwill SA
    Clin Cancer Res; 2022 Aug; 28(15):3387-3399. PubMed ID: 35121624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade.
    Zuo S; Wei M; Xu T; Kong L; He B; Wang S; Wang S; Wu J; Dong J; Wei J
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations.
    Willoughby JE; Dou L; Bhattacharya S; Jackson H; Seestaller-Wehr L; Kilian D; Bover L; Voo KS; Cox KL; Murray T; John M; Shi H; Bojczuk P; Jing J; Niederer H; Shepherd AJ; Hook L; Hopley S; Inzhelevskaya T; Penfold CA; Mockridge CI; English V; Brett SJ; Srinivasan R; Hopson C; Smothers J; Hoos A; Paul E; Martin SL; Morley PJ; Yanamandra N; Cragg MS
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 38964788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation.
    Han JH; Cai M; Grein J; Perera S; Wang H; Bigler M; Ueda R; Rosahl TW; Pinheiro E; LaFace D; Seghezzi W; Williams SMG
    Front Immunol; 2020; 11():573405. PubMed ID: 33117369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fc-Fc interactions and immune inhibitory effects of IgG4: implications for anti-PD-1 immunotherapies.
    Zhang W; Chen X; Chen X; Li J; Wang H; Yan X; Zha H; Ma X; Zhao C; Su M; Hong L; Li P; Ling Y; Zhao W; Xia Y; Li B; Zheng T; Gu J
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38925680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy.
    Schoonderwoerd MJA; Koops MFM; Angela RA; Koolmoes B; Toitou M; Paauwe M; Barnhoorn MC; Liu Y; Sier CFM; Hardwick JCH; Nixon AB; Theuer CP; Fransen MF; Hawinkels LJAC
    Clin Cancer Res; 2020 Jul; 26(14):3831-3842. PubMed ID: 32332012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation.
    Muik A; Altintas I; Gieseke F; Schoedel KB; Burm SM; Toker A; Salcedo TW; Verzijl D; Eisel D; Grunwitz C; Kranz LM; Vormehr M; Satijn DPE; Diken M; Kreiter S; Sasser K; Ahmadi T; Türeci Ö; Breij ECW; Jure-Kunkel M; Sahin U
    Oncoimmunology; 2022; 11(1):2030135. PubMed ID: 35186440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
    Allard B; Pommey S; Smyth MJ; Stagg J
    Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy.
    Chen X; Song X; Li K; Zhang T
    Front Immunol; 2019; 10():292. PubMed ID: 30863404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges.
    Javed SA; Najmi A; Ahsan W; Zoghebi K
    Front Immunol; 2024; 15():1383456. PubMed ID: 38660299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis.
    Dahan R; Sega E; Engelhardt J; Selby M; Korman AJ; Ravetch JV
    Cancer Cell; 2015 Sep; 28(3):285-95. PubMed ID: 26373277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy.
    Lauret Marie Joseph E; Kirilovsky A; Lecoester B; El Sissy C; Boullerot L; Rangan L; Marguier A; Tochet F; Dosset M; Boustani J; Ravel P; Boidot R; Spehner L; Haicheur-Adjouri N; Marliot F; Pallandre JR; Bonnefoy F; Scripcariu V; Van den Eynde M; Cornillot E; Mirjolet C; Pages F; Adotevi O
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34230108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
    Han X; Li H; Zhou D; Chen Z; Gu Z
    Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.
    Arce Vargas F; Furness AJS; Solomon I; Joshi K; Mekkaoui L; Lesko MH; Miranda Rota E; Dahan R; Georgiou A; Sledzinska A; Ben Aissa A; Franz D; Werner Sunderland M; Wong YNS; Henry JY; O'Brien T; Nicol D; Challacombe B; Beers SA; ; ; ; Turajlic S; Gore M; Larkin J; Swanton C; Chester KA; Pule M; Ravetch JV; Marafioti T; Peggs KS; Quezada SA
    Immunity; 2017 Apr; 46(4):577-586. PubMed ID: 28410988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonfucosylation of an anti-TIGIT antibody enhances FcγR engagement, driving innate immune activation and antitumor activity.
    Smith AJ; Thurman RE; Zeng W; Grogan B; Lucas S; Gutierrez G; Heiser RA; Wo SW; Blackmarr A; Peterson S; Gardai SJ
    Front Immunol; 2023; 14():1280986. PubMed ID: 38022590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.